Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib PK and Safety in Advanced Solid Tumors with Hepatic Impairment
NCT02997176Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in solid tumor (advanced stage) (4 arms), sponsored by Pfizer. Primary endpoints: Area Under the Free Plasma Concentration Time Curve From Zero to 24 Hours, Maximum Observed Plasma Concentration at Day 22 and 2 more. Started Sep 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02997176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997176.